UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus

Goulden, B; Isenberg, D; (2021) Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus. Expert Opinion on Biological Therapy , 21 (4) pp. 519-528. 10.1080/14712598.2021.1841164. Green open access

[thumbnail of Isenberg_Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus_AAM.pdf]
Preview
Text
Isenberg_Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus_AAM.pdf - Accepted Version

Download (242kB) | Preview

Abstract

INTRODUCTION: The type 1 interferon pathway is known to play a role in the immunopathology of systemic lupus erythematosus (SLE). As a result, biologic agents targeting this pathway have been developed and are currently being investigated in clinical trials. AREAS COVERED: We review the biologic agents which have been developed to antagonize type I interferons in SLE. We focus on anifrolumab, a type I interferon receptor antagonist, and consider the complexities of defining efficacy in SLE clinical trials. EXPERT OPINION: Anifrolumab shows promise as an addition to the SLE therapeutic armamentarium. Despite discordant results between its two phase III studies, there is a convincing suggestion of benefit in both trials to encourage the view that this approach might be effective. Data acquired thus far look particularly useful for cutaneous disease. We await data on its effect on renal, pulmonary, cardiac, and central nervous system involvement, on patient reported outcomes, and its safety and efficacy with long-term use.

Type: Article
Title: Anti-IFNαR Mabs for the treatment of systemic lupus erythematosus
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1080/14712598.2021.1841164
Publisher version: https://doi.org/10.1080/14712598.2021.1841164
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: Anifrolumab, anti-interferon, interferon, lupus activity, systemic Lupus Erythematosus
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10114292
Downloads since deposit
116Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item